The draft rules provide for two full-scope facilitator licenses, “Facilitator” and “Clinical Facilitator.” As a baseline, both licenses require a Basic Life Support (BLS) certification,
As we mentioned in our coverage of the Kentucky effort, bringing a drug through the FDA approval process is expensive, with costs often measured in
In our latest Psychedelic Patent Analysis, we take a deep dive into recent patent-related developments at two companies that are both pursuing 5-MeO-DMT for treatment-resistant
Featured content in this Issue: This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to
On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a two-day virtual meeting, Advancing Psychedelic Clinical Study Design. The below
*** Production, Cultivation, and Testing The Products, Research, and Data subcommittee, which produced the following recommendations, relied heavily on outside experts in the form of
Colorado’s Regulated Natural Medicine Program At-a-Glance Facilitators will hold one of three primary license types: Wellness; Behavioral Health; and Medical. All facilitators will be required
On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a virtual event, Advancing Psychedelic Clinical Study Design. Using the FDA’s draft guidance
This January we were treated to a mix of novel psychedelic trials and an unusually large amount of re-analyses of earlier studies. Ibogaine was researched
The above publications received comments from the researchers we surveyed. Here are further 2023 publications that Michael included in his list. *** Jones, G., Herrmann,